Stopping the TB Scourge: A Call to Action

The devastating impact of tuberculosis is still prevalent in low-income countries, with over 1 million lives claimed annually. Despite international efforts, the disease remains the world's leading infectious-disease killer. However, advancements in screening, prevention, and treatment now make significant progress possible, but only if they are implemented.

Key Takeaways:

• In 2022, the global TB case rate had decreased by a quarter since 2000, and death rates had halved over the same period, demonstrating the effectiveness of international public health efforts.
• TB case detection increased by almost 40% in Nigeria in a single year using a combination of ultraportable X-ray equipment and fast-turnaround molecular tests.
• Newer TB medication regimens are shorter, more effective, and less toxic, with a 12-week preventive regimen now available instead of up to nine months of daily medications.
• USAID, in partnership with nonprofit buyers, has negotiated lower prices for TB medicines and tests by 20-55% since last fall, allowing millions more people to be reached within existing budgets.
• In India, the government's increased funding for TB, now exceeding $1.8 billion over four years, has led to positive results nationwide, with nearly 90% of estimated TB cases diagnosed and high treatment success rates.
• Clinical trials of five promising TB vaccines are now underway, demonstrating a steady stream of innovations in the fight against the disease.

Statistics:

• TB claims over 1 million lives annually.
• The disease is responsible for 25% of all deaths in the United States, but this is no longer a widespread threat due to the availability of effective tools.
• International public health efforts have cut global TB case rates by a quarter and death rates by half since 2000.
• TB is 25 times more prevalent in India, where one in every 90 people is infected, compared to the United States (one in 32,000).
• In Delhi's homeless population, one in every 12 people has TB.
• Conventional TB screening tools are either expensive or slow to produce results.
• Common medication regimens require daily doses for months and sometimes years, with potential side effects including nausea and organ damage.
• The Global Fund to Fight AIDS, Tuberculosis and Malaria has provided crucial support for countries combating TB.
• The US government has provided additional support through agreements with hard-hit countries, including the Philippines and Ethiopia.

Sources:

• This article appeared in print on page SR9.
• The New York Times is committed to publishing a diversity of letters to the editor (nytimes.com).
• Letters to the editor: letters@nytimes.com
• Follow The New York Times Opinion section on Facebook, Instagram, TikTok, WhatsApp, X, and Threads.